---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108030"
form_type: "8-K"
ticker: "HYPR"
cik: "0001833769"
company_name: "Hyperfine, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:22.607879+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hyperfine Q2 revenue $2.7M (+26% QoQ), net loss $9.2M; FDA clearances for Optive AI and next-gen Swoop

## Summary
- Revenue $2.7M, up 26% from Q1; sold 8 commercial Swoop systems vs 6 in Q1.
- Net loss $9.2M ($0.12/share) vs $9.4M in Q1; gross margin 49.3%, up 800 bps QoQ.
- FDA cleared Optive AI software and next-generation Swoop system; commercial rollout begun.
- Completed neurology office pilot; full-scale commercial launch initiated.
- FY 2025 revenue guidance: 10-20% over 2024; cash burn guided to $27-29M, down 27% YoY.

## SEC filing metadata
- accession: 0000950170-25-108030
- form_type: 8-K
- ticker: HYPR
- cik: 0001833769
- company_name: Hyperfine, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833769/000095017025108030/0000950170-25-108030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833769/000095017025108030/hypr-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108030
- JSON: https://secwatch.observer/filing/0000950170-25-108030.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.